Incannex Healthcare Inc. IXHL
Regular-session close
After hours · Nov 19, 4:00 PM ET
- YTD
- -83.80%
- 1 year
- -82.58%
5D -0.03 (-1.52%)
- Market cap
- 21.83M
- Revenue (ttm)
- 12.00K
- EPS (ttm)
- -1.25
- Shares out
- 17.64M
- Forward P/E
- -0.86
- YTD return
- -83.80%
- 1-year return
- -82.58%
- Volume
- 192.50K
- Avg volume
- 87.43K
- Open
- 1.76
- Previous close
- 1.75
- Day's range
- 1.74 – 2.04
- 52-week range
- 1.61 – 14.91
- Beta
- 2.21
Key statistics
- 50-day average
- 2.08
- 200-day average
- 2.40
- Enterprise value
- 29.80M
- Price / sales
- 2469.99
- Price / book
- 2.64
- Free cash flow
- -9.32M
- Total cash
- 5.86M
- Total debt
- 373.00K
- Return on equity
- -115.22%
- Short % of float
- 0.37%
Fundamental scorecard
5 of 25 checks passed on IXHL’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | 0.00 | — | — | — |
| Sep 30, 2024 | Jun 1, 2024 | 0.00 | -0.39 | — | — |
About Incannex Healthcare Inc.
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Australia
- Website
- incannex.com
News
Your note
Sign in to keep a note on IXHL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANASTASSOV GEORGE | Director | Stock Award(Grant) | Dec 20, 2023 | 769,721 |
| CLARK ROBERT | Director | Stock Award(Grant) | Dec 20, 2023 | 100,000 |
| LATHAM JOEL | Chief Executive Officer | Stock Award(Grant) | Dec 20, 2023 | 1,577,480 |
| SWAN JOSEPH | Officer | Stock Award(Grant) | Oct 22, 2024 | 100,476 |
| VALENTINE TROY ROBERT | Director | Stock Award(Grant) | Dec 20, 2023 | 1,036,510 |
| WIDDOWS PETER | Director | Stock Award(Grant) | Dec 20, 2023 | 270,847 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tidal Investments, LLC | 0.74% | 130,026 | 218.44K | Sep 29, 2024 |
| AdvisorShares Investments, LLC | 0.72% | 126,990 | 213.34K | Sep 29, 2024 |
| Morgan Stanley | 0.22% | 38,853 | 65.27K | Sep 29, 2024 |
| Virtu Financial LLC | 0.21% | 36,622 | 61.52K | Sep 29, 2024 |
| Bridgeway Capital Management, Inc. | 0.14% | 25,000 | 42.00K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.14% | 24,152 | 40.58K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.81% | 142,545 | 239.47K | Oct 30, 2024 |
| Amplify ETF Tr-Amplify Alternative Harvest ETF | 0.74% | 130,026 | 218.44K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.14% | 25,000 | 42.00K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 7,963 | 13.38K | Oct 30, 2024 |
